Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.48 USD | +4.39% | -.--% | -6.75% |
Apr. 30 | Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024 | CI |
Apr. 30 | Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer | CI |
Evolution of the average Target Price on Innovent Biologics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Innovent Biologics, Inc.
Nomura | |
UBS |
EPS Revisions
- Stock Market
- Equities
- 1801 Stock
- IVBIY Stock
- Consensus Innovent Biologics, Inc.